MRD in PAAD Adjuvant Therapy

Inclusion criteria

• Here's the translated and polished version of your content:

• Patients clinically diagnosed with pancreatic cancer, staged I-III (AJCC V8.0), who are scheduled to undergo curative surgery.
• No restrictions on gender; age between 18 and 70 years.
• Eastern Cooperative Oncology Group (ECOG) performance status score: ≤2.
• Expected survival time of ≥3 months.
• Willingness to comply with the study protocol for testing, treatment, and follow-up; consent to provide necessary clinical, pathological, and follow-up data for the study; and agreement to use the research data for future studies and product development.
• Voluntary participation in this clinical study, with an understanding of the study procedures and the ability to sign an informed consent form.

Exclusion criteria

• Patients who have had other malignancies within the five years prior to this study.
• Patients who have received any antitumor treatment within six months prior to enrollment.
• Patients with concomitant diseases that, in the investigator's judgment, pose a serious risk to patient safety or could affect the patient's ability to complete the study (such as poorly controlled hypertension, severe diabetes, thyroid disorders, psychiatric disorders, etc.), or any other conditions deemed unsuitable for participation.